Didier Bessis

Didier Bessis

Auto-generated profile, based on publicly available information

Didier Bessis

Department of Dermatology, Saint-Eloi Hospital, Reference Centre for Rare Skin Diseases and University of Montpellier, Montpellier, France; INSERM U1058, Montpellier, France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 August 2013 in Human Mutation
Verified
Journal Article
Closed access
PDF file
NRNicole Revencu
Nicole Revencu
LBLaurence M. Boon
Laurence M. Boon
AMAntonella Mendola
Antonella Mendola
MCMaria Rosa Cordisco
Maria Rosa Cordisco
JDJosée Dubois
Josée Dubois
Miikka VikkulaMiikka Vikkula
Miikka Vikkula
Capillary malformation–arteriovenous malformation (CM–AVM) is an autosomal‐dominant disorder, caused by heterozygous RASA1 mutations, and manifesting multifocal CMs and high risk for fast‐flow lesions. A limited number of patients have been reported, raising the question of the phenotypic borders. We identified new patients with a clinical diagnosis of CM–AVM, and patients with overlapping phenotypes. RASA1 was screened in 261 index patients with: CM–AVM (n = 100), common CM(s) (port‐wine stain; n = 100), Sturge–Weber syndrome (n = 37), or isolated AVM(s) (n = 24). Fifty‐eight distinct RASA1 mutations (43 novel) were identified in 68 index patients with CM–AVM and none in patients with other phenotypes. A novel clinical feature was identified: cutaneous zones of numerous small white pale halos with a central red spot. An additional question addressed in this study was the “second‐hit” hypothesis as a pathophysiological mechanism for CM–AVM. One tissue from a patient with a germline RASA1 mutation was available. The analysis of the tissue showed loss of the wild‐type RASA1 allele. In conclusion, mutations in RASA1 underscore the specific CM–AVM phenotype and the clinical diagnosis is based on identifying the characteristic CMs. The high incidence of fast‐flow lesions warrants careful clinical and radiologic examination, and regular follow‐up.

1 July 2017 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
SGSylvie Grandemange
Sylvie Grandemange
ESElodie Sanchez
Elodie Sanchez
PLPascale Louis-Plence
Pascale Louis-Plence
FMFrédéric Tran Mau-Them
Frédéric Tran Mau-Them
DBDidier Bessis
Didier Bessis
DGDavid Geneviève
David Geneviève
Objectives Inflammasomes are multiprotein complexes that sense pathogens and trigger biological mechanisms to control infection. Nucleotide-binding oligomerisation domain-like receptor (NLR) containing a PYRIN domain 1 (NLRP1), NLRP3 and NLRC4 plays a key role in this innate immune system by directly assembling in inflammasomes and regulating inflammation. Mutations in NLRP3 and NLRC4 are linked to hereditary autoinflammatory diseases, whereas polymorphisms in NLRP1 are associated with autoimmune disorders such as vitiligo and rheumatoid arthritis. Whether human NLRP1 mutation is associated with autoinflammation remains to be determined. Methods To search for novel genes involved in systemic juvenile idiopathic arthritis, we performed homozygosity mapping and exome sequencing to identify causative genes. Immunoassays were performed with blood samples from patients. Results We identified a novel disease in three patients from two unrelated families presenting diffuse skin dyskeratosis, autoinflammation, autoimmunity, arthritis and high transitional B-cell level. Molecular screening revealed a non-synonymous homozygous mutation in NLRP1 (c.2176C>T; p.Arg726Trp) in two cousins born of related parents originating from Algeria and a de novo heterozygous mutation (c.3641C>G, p.Pro1214Arg) in a girl of Dutch origin. The three patients showed elevated systemic levels of caspase-1 and interleukin 18, which suggested involvement of NLRP1 inflammasome. Conclusions We demonstrate the responsibility of human NLRP1 in a novel autoinflammatory disorder that we propose to call NAIAD for NLRP1-associated autoinflammation with arthritis and dyskeratosis. This disease could be a novel autoimmuno-inflammatory disease combining autoinflammatory and autoimmune features. Our data, combined with that in the literature, highlight the pleomorphic role of NLRP1 in inflammation and immunity. Trial registration number NCT02067962; Results.

1 December 2016 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MFMarie-Louise Frémond
Marie-Louise Frémond
MRMathieu Paul Rodero
Mathieu Paul Rodero
NJNadia Jeremiah
Nadia Jeremiah
ABAlexandre Belot
Alexandre Belot
EJEric Jeziorski
Eric Jeziorski
BNBénédicte Neven
Bénédicte Neven

10 November 2014 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MJMarie Jachiet
Marie Jachiet
BFBéatrice Flageul
Béatrice Flageul
ADAlban Deroux
Alban Deroux
AQAlain Le Quellec
Alain Le Quellec
FMFrançois Maurier
François Maurier
FGfor the French Vasculitis Study Group
for the French Vasculitis Study Group
Objective: Hypocomplementemic urticarial vasculitis (HUV) is an uncommon vasculitis of unknown etiology that is rarely described in the literature. We undertook this study to analyze the clinical spectrum and the therapeutic management of patients with HUV.Methods: We conducted a French nationwide retrospective study that included 57 patients with chronic urticaria, histologic leukocytoclastic vasculitis, and hypocomplementemia. We assessed clinical and laboratory data and evaluated the patients' cutaneous and immunologic responses to therapy. We evaluated treatment efficacy by measuring the time to treatment failure.Results: Urticarial lesions were typically more pruritic than painful and were associated with angioedema in 51% of patients, purpura in 35%, and livedo reticularis in 14%. Extracutaneous manifestations included constitutional symptoms (in 56% of patients) as well as musculoskeletal involvement (in 82%), ocular involvement (in 56%), pulmonary involvement (in 19%), gastrointestinal involvement (in 18%), and kidney involvement (in 14%). Patients with HUV typically presented with low C1q levels and normal C1 inhibitor levels, in association with anti‐C1q antibodies in 55% of patients. Hydroxychloroquine or colchicine seemed to be as effective as corticosteroids as first‐line therapy. In patients with relapsing and/or refractory disease, rates of cutaneous and immunologic response to therapy seemed to be higher with conventional immunosuppressive agents, in particular, azathioprine, mycophenolate mofetil, or cyclophosphamide, while a rituximab‐based regimen tended to have higher efficacy. Finally, a cutaneous response to therapy was strongly associated with an immunologic response to therapy.Conclusion: HUV represents an uncommon systemic and relapsing vasculitis with various manifestations, mainly, musculoskeletal and ocular involvement associated with anti‐C1q antibodies, which were found in approximately half of the patients. The best strategy for treating HUV has yet to be defined.

29 June 2004 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
WJW. Jacot
W. Jacot
DBD. Bessis
D. Bessis
EJE. Jorda
E. Jorda
MYM. Ychou
M. Ychou
MFM. Fabbro
M. Fabbro
BGB. Guillot
B. Guillot

1 April 2012 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
ACAnne Cosnes
Anne Cosnes
CFCamille Francès
Camille Francès
PDPierre Duhaut
Pierre Duhaut
NZNoël ZAHR
Noël ZAHR
BSBoutros Soutou
Boutros Soutou
NCNathalie Costedoat-Chalumeau
Nathalie Costedoat-Chalumeau
Oral antimalarial agents, most commonly hydroxychloroquine sulfate, are considered the first-line systemic treatment for cutaneous lupus erythematosus (CLE).1 The prescribed hydroxychloroquine sulfate dosage theoretically depends on the patient's weight, with a maximal daily dose of 6.0 to 6.5 mg/kg adjusted to the ideal body weight (calculated in daily use as [body length in centimeters − 100] − 10% for men and [body length in centimeters− 100] − 15% for women).2 Nonetheless, the standard daily dosage in France is frequently 2 tablets of hydroxychloroquine sulfate (ie, 400 mg/d), regardless of the patient's height and weight. The few studies that have addressed the pharmacokinetic variables underlying the management of hydroxychloroquine therapy in systemic diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE)3-5 reveal great interindividual variability in blood hydroxychloroquine concentrations and thus raise the question of a relation between concentration and efficacy and of the utility of monitoring these concentrations. We have reported that a low blood hydroxychloroquine concentration is a marker of SLE activity and a predictor of lupus flares in patients with this disease and suggested a target blood hydroxychloroquine level of 1000 ng/mL for them.5